The US government’s plan to negotiate drug prices with pharmaceutical companies is politically popular but faces opposition from drug firms who say it will stifle innovation. Amanda Starc, associate professor of strategy at Kellogg, argues that the current pharmaceutical pricing system is complex and the government’s plan doesn’t address this complexity or recognize the long-term costs of price regulation. She suggests that better policies would encourage competition and transparency in the market, such as increasing the size of the drug market by allowing more imported drugs, speeding up the FDA approval process for generic drugs, and revealing how prices are negotiated.
American Support for Government’s Drug Pricing Plan
Political consensus surrounds the government’s new plan to reduce drug costs, a proposal backed by Democrats for over two decades (source). Facilitated by the Inflation Reduction Act, the Congressional Budget Office projects this initiative will save taxpayers $98 billion in the next decade.
However, pharmaceutical companies, facing potential heavy fines and loss of huge market share, disagree. They argue this plan would stifle innovation and reduce the production of groundbreaking drugs. Six companies have already initiated lawsuits against the plan.
Understanding Drug Pricing and its Complexity
When it comes to drug pricing, Amanda Starc, an associate professor of strategy, warns against oversimplifying the narrative. She points out that drug prices result from intricate market dynamics, with high costs often associated with advanced therapeutic options.
Starc suggests policies promoting market competition and transparency, rather than price dictation, may provide a more sustainable solution.
The pharmaceutical market is unique in its interaction with insurance. The price paid by insured customers often differs significantly from the “net” and “list” prices negotiated by their insurers and set by the manufacturers, respectively.
Reforming Drug Pricing: A New Approach
With 50 million Americans receiving prescription medication through Medicare Part D and drug prices rising, the government is pressuring pharmaceutical companies to reduce costs. But reduced prices may also mean reduced profits and potentially less industry advancements. Starc’s research paper emphasizes transparency in price negotiations and increased market competition.
She highlights the need for more competition in the industry, currently dominated by a few key players. Greater transparency surrounding the role of pharmacy benefit managers, who negotiate price rebates, is also recommended (source).
Moving Towards a “Healthier” Drug Market
Starc and her colleague Craig Garthwaite propose policies for improvement. They suggest encouraging competition among firms at all value chain levels, advocating for increased drug imports, and enhancing regulatory agencies like FDA’s capacity to ensure drug quality.
They also urge faster FDA approval for generic drugs, allowing more firms to enter the market. These changes, they believe, would enhance competition and transparency, creating a healthier drug market.